Genentech will lay off 93 employees at its South San Francisco headquarters effective October 8, 2024. The layoffs will primarily impact scientists, engineers, managers, analysts, and one vice president.
The announcement follows the recent closure of Genentech's cancer immunology group as the company shifts focus within its cancer research investments. A spokesperson previously stated that this decision was due to changes in the science of immuno-oncology, leading to the integration of cancer immunology research with molecular oncology programs.
This marks Genentech's second round of layoffs in 2024. In April, the company reduced its workforce by approximately 3%, affecting over 400 positions across multiple departments. However, no job cuts were reported at its parent company, Roche.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.